Opinion · 30 Sep 2022
Conference abstractPublished 24 Sep 2012
Acquired haemophilia A
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder characterized by inhibitory antibodies directed against circulating coagulation factor (F) VIII. The incidence of AHA has been estimated to be 0.2 to 1.0 per million per year. Typically, patients with no previous personal or family history of a bleeding present with spontaneous bleeds and an isolated prolonged activated partial thromboplastin time. The final diagnosis is made on the basis of low FVIII levels and the presence of FVIII inhibitor. The pattern of bleeding varies from mild bleeding requiring no treatment, to severe life-threatening hemorrhage, with 9 to 22% mortality. The mainstays of the treatment are the management of acute bleeding and the inhibitor eradication. First-line treatment of bleeding is with a bypassing agent. Two available licensed regimens are recombinant factor VIIa and the activated prothrombin complex concentrate. The risk of severe life-threatening bleeding continues until the FVIII antibody has been eradicated, therefore immunosuppression should be commenced in all patients as soon as the diagnosis has been made. Commonly used regimens are steroids alone or steroids combined with cyclophosphamide. The anti CD20 monoclonal antibody, rituximab, has shown good results in patients who do not respond to standard immunosuppressive agents. AHA usually presents to clinicians without prior experience of the disease, therefore it is important to increase the awareness of this disorder among health care professionals. Early recognition, rapid diagnosis and prompt referral to a specialized centre are important to optimize the treatment and improve the outcome for this patient group.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 11 Jul 2022
COVID-19 vaccine Acquired Haemophilia: A case study and literature review
Conference abstract · 24 Sep 2012
Acquired haemophilia A
Mini review · 26 May 2023
Acquiring Pregnant Women Treated through a Mobile Clinic: Jordanian Moms' Personal Stories
Case report · 12 Jul 2022
Acquired Hematometra and Ematocolpos: A Rare Condition in a Perimenopausal Reproductive Female
More from this journal
The newest in Gynecology & Obstetrics.
Short communication · 30 Apr 2026
Vitamin D and Polycystic Ovary Syndrome: A Research Progress Review
Conference abstract · 19 Nov 2025
Loss of lncRNAs 1700101O22Rik and 1700027A15Rik causes sperm malformation and subfertility
Conference abstract · 19 Nov 2025
Linking Mitochondrial Fatty Acid Metabolism to Follicular Health: A Novel Perspective on Premature Ovarian Insufficiency
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalGynecology & Obstetrics
- SubjectReproductive Medicine & Gynaecology
- BylineArticles whose byline prints “Roganovic Jelena”

